Ildefonso Rodriguez-Rivera on Muck Rack

Ildefonso Rodriguez-Rivera

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ildefonso

Contact Ildefonso, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial - Nature Medicine

|
By Matthew D. Galsky, Charlene M. Mantia, Michaela Bowden, Joaquim Bellmunt, Benjamin Garmezy, Gopa Iyer, Daniel P. Petrylak, Drew Rasco, Shilpa Gupta, Phuong Nguyen Verified, Phương Nguyên, Jennifer Tepper, Alex Rossi Verified, Jennifer A Mertz, Evisa Gjini, Michael Meyers, Matthew I. Milowsky, Xin Gao, Ildefonso Rodriguez-Rivera, Yelena Mikhailov, Adarsh Joshi, Bijal Kakrecha, Anne Marie Costa, Carolyn McCrone
| Nature Verified
Abstract Peroxisome proliferator-activated receptor gamma (PPARγ) is a master regulator of luminal lineage in urothelial carcinoma. FX-909 is a first-in-class oral small-molecule PPARγ inverse agonist. Here we report the first part of FX-909-CLINPRO-1, a phase 1A 3 + 3 dose-escalation study of FX-909, that enrolled 56 patients with advanced solid tumors, including 46 with urothelial carcinoma.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified